Remission of Korean Non-Insulin Dependent Diabetes Mellitus by Continuous Subcutaneous Insulin Infusion Treatment Konkuk University Diabetic Center Soobong.

Slides:

Advertisements

Similar presentations

BLOOD GLUCOSE MONITORING Center For Diabetes Education at Tulsa Regional Medical Center.

Advertisements

Biomedical Research Models, Inc., Worcester, MA

Epidemiology of Diabetes Mellitus. Definition: -Diabetes mellitus is a group of diseases marked by high levels of blood glucose resulting from defects.

Role of Amylin and Glucagon in Postprandial Glycemic Excursions in Pediatric Type 1 Diabetes. Rubina Heptulla MD, Luisa M. Rodriguez MD and Morey W. Haymond.

Positive Implications of Initiating Insulin Pump Therapy at Diagnosis of Type 1 Diabetes Ramchandani, Neesha 1 ; Ten, Svetlana 1 ; Anhalt, Henry 2 ; Sinha,

TIME TO ACT Type 2 diabetes, the metabolic syndrome and cardiovascular disease in Europe CONTENTS Section One: Background to type 2 diabetes, the metabolic.

© 2004, John Walsh, PA, CDE Intelligent Devices A Smart Pen demonstrates possibilities for intelligent diabetes devices by John Walsh, P.A., C.D.E. Smart.

Advanced Pumping. Objectives: Identify situations to utilize temporary basal rate in pump therapy patients. Identify examples of when to use combination.

Diabetes Self Management Laura Wintersteen-Arleth, MN, RN,CDE

Surgery In Diabetes Mellitus (DM)

ADA Criteria for the diagnosis of diabetes Table 3—Criteria for the diagnosis of diabetes 1. A1C ≥ 6.5%. The test should be performed in a laboratory.

Diabetes and Self Monitoring

 Objectives: ◦ Explain the signs and symptoms of high blood glucose. ◦ Participate in flashcards for terminology ◦ Identify normal limits, high limits,

1 Type 1 Diabetes Mellitus Treatment. 2 Goals of T1DM Management Utilize intensive therapy aimed at near-normal BG and A1C levels Prevent diabetic ketoacidosis.

Susan Alexander, DNP, CNS, CRNP, BC- ADM College of Nursing University of Alabama in Huntsville Clinical Affiliation: Outpatient Diabetes Self-Management.

A CASE from Weight Loss Clinic

Block 9 Board Review Endocrine/Rheum 14Feb14 Chauncey D. Tarrant, M.D. Chief of Residents

Diagnosis and Management of Hyperglycemic Crises

Guidelines for the Early Management of Diabetic Ketoacidosis in Children Guidelines for the Early Management of Diabetic Ketoacidosis in Children Michael.

Diabetes Update Matt Bouchonville, MD Endocrinology Division University of New Mexico ACP New Mexico Chapter Scientific Meeting November 7, 2014

Endocrine Module 1b. Pancreas Gland 6 ” long Horizontal Behind stomach Upper left abdominal quadrant Both endocrine & exocrine functions.

Judith Croasmun. HGA1C: What is it??  The A1C is the average of the blood sugar over a 2-3 month time period.  The A1C measures the amount of sugar.

Recovery of the β–cell function both in new and long-standing type 2 diabetic patients through long-term treatment with continuous subcutaneous insulin.

Clinical Protocol Using Insulin Pump Easy Guideline for Initiating Insulin Pumps on Type 2 Diabetes Patients.

Diabetes Mellitus. What´s Diabetes? Diabetes is a group of metabolic alterations that lead to the increase of blood glucose concentration. Why there is.

Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus Matthew Faiman.

DIABETES MELLITUS IN CHILDREN: CLINICAL FEATURES, DIAGNOSTICS AND TREATMENT Prof. H.A. Pavlyshyn.

Treatment with medical waters in Hungary prof. L. Halmy Hungary.

Naseem Sohpal Lead Diabetes Specialist Nurse

Beginning of the chapter Diabetes and genetics (Diabetes Sensor) 41.

Diabetes Mellitus in a pre- operative patient: associated risks and complications of general anesthesia Julie L Williams M.D., M.S. CA-1.

Fatty Acid & Protein Metabolism. Carbohydrate metabolism is WAY groovy baby! But what does Jon expect us to know from all this chemistry mumbo jumbo?

Materials and Methods Phase 1 Evaluated acute effects on fasting blood glucose and on post-oral glucose Groups 1 and 3 received distilled water Groups.

Endocrine and Metabolic Disorders Lectures 8 I.Kuziv, MD, PhD.

Identify barriers to effective patient teaching. Identify and teach to the standards of medical care for the management of Type 2 diabetes Describe the.

Diabetic Ketoacidosis DKA PHCL 442 Lab Discussion 6 Raniah Al-Jaizani M.Sc.

Diabetes. The Food You Eat is Broken Down Into Glucose to Supply Energy to Your Cells.

Dixie L. Thompson chapter 20 Exercise and Diabetes.

Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.

Diabetes, Surgery and GKI’s Maureen Wallymahmed Nurse Consultant - Diabetes.

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57) Last modified January 2015.

Date of download: 6/24/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.

Date of download: 6/26/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.

Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.

Key publication slides

Fig. 1 Examples of Insulin pump systems

Copyright © 2004 American Medical Association. All rights reserved.

Key publication slides

From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.

Continuous Subcutaneous Insulin Infusion (CSII) [Insulin Pump]

Utilizing New Technologies and Insulins for a Tighter Grip on PPG

Clinical recommendations in the management of the patient with type 1 diabetes on insulin pump therapy in the perioperative period: a primer for the anaesthetist

Nilotinib 300 mg bid Nilotinib 400 mg bid Imatinib 400 mg qd n Median

Jean L. Chan, MD, Martin J. Abrahamson, MD Mayo Clinic Proceedings

Efficacy of ginger for treating Type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials James W. Daily, Mini Yang, Da Sol.

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.

Modern strategies for management of glycaemia in type 1 diabetes

James F. List, Jean M. Whaley Kidney International

GH dose 12 months of treatment 24 months of treatment Low Medium High

Jennifer McVean, MD September 23, 2010

Low-dose hormone therapy and carbohydrate metabolism

INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.

Glucose, insulin, and AGE levels during an OGC before and after RT

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

(A) Changes in BG level during REST, ST-EX and BI-EX trials in the combined (ALL) group. * and ** indicate the presence of significant differences (p

Distribution of daily frequency of BGM

NEW INSULIN ORDER SETS (NON-ICU AREAS)

Presentation transcript:

Remission of Korean Non-Insulin Dependent Diabetes Mellitus by Continuous Subcutaneous Insulin Infusion Treatment Konkuk University Diabetic Center Soobong Choi, M.D. Ph.D., Sunmin Park Diabetes/Metabolism Research and Review, March, 2003

Remission Pattern REMISSION CSII TX. (Months) (Case No.)

INSULIN DOSEBLOOD GLUCOSE (wks) (U/day)(mg/dL) p< 0.05 (wks) Non-Remission.Remission. Changes of blood glucose levels and total daily insulin dosage

Fasting BG Post-prandial BG (wks) mmol/L (wks) ** ### **Significantly different from remission group at p<0.01. ### Significantly different from the baseline at p< ### Non-Remission.Remission. Changes of Blood Glucose after CSII

Hemoglobin A 1c BMI %kg/m 2 (wks) ### Significantly different from the baseline at p< # p<0.05. ### Non-Remission.Remission. Changes of Hemoglobin A1c and BMI after CSII

Fasting c-peptide Post-prandial c-peptide (wks) nmol/L (wks) * * * ** ## **Significantly different from remission group at p<0.01. * p<0.05. ## Significantly different from the baseline at p<0.01. Non-Remission.Remission. Plasma C-Peptide after CSII

(yrs) Non-Remiss. Case Remission Case Duration Remission and Duration